ResMed (NYSE:RMD – Get Free Report) had its price target hoisted by equities researchers at Royal Bank Of Canada from $234.00 to $244.00 in a research report issued to clients and investors on Friday,Benzinga reports. Royal Bank Of Canada’s price target suggests a potential upside of 15.18% from the stock’s current price. KeyCorp cut their price target on ResMed from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday. UBS Group restated a “buy” rating and issued a $300.00 price target on shares of ResMed in a research report on Tuesday, July 21st. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $240.17.